Company research
Beta Bionics, Inc.
CIK 1674632Updated Sep 24, 2026
SecurityBBNX · NASDAQ · equity
Name history
Beta Bionics, Inc · through Jan 6, 2025
BBNX price & chart
Loading TradingView…
NASDAQ:BBNX on TradingView ↗About the company
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to u…
In the news
$BBNX Stock Notification: Beta Bionics has been Sued for Securities Fraud after Medical Device Safety Issues Disclosed – Investors are Alerted to Contact BFA Law by November 3 ↗
ATTENTION NASDAQ: BBNX INVESTORS: Contact Berger Montague About a Beta Bionics, Inc. Class Action Lawsuit ↗
BBNX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Beta Bionics Inc. ↗
Recent filings
144 filing
4 filing
4 filing
Other Events
Items 8.01, 9.01
424B5 filing
Show 5 more recent filings
144 filing
144 filing
FWP filing
424B5 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 328,743,000Source | 149,645,000Source | 110,040,000Source |
| Property, Plant and Equipment, NetUSD | 8,600,000Source | 4,776,000Source | 2,476,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 31,576,000Source | 30,432,000Source | 26,566,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 17,118,000Source | 11,996,000Source | 4,448,000Source |
| Inventory, NetUSD | 21,722,000Source | 13,320,000Source | 1,245,000Source |
| Assets, CurrentUSD | 267,905,000Source | 132,923,000Source | 103,621,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,840,000Source | 4,032,000Source | 1,183,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,627,000Source | 6,645,000Source | 3,722,000Source |
| Other Assets, NoncurrentUSD | 180,000Source | 150,000Source | 121,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 41,133,000Source | 73,632,000Source | 51,432,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 4,000Source | — | — |
| Additional Paid in CapitalUSD | 657,140,000Source | 51,311,000Source | 26,421,000Source |
| Retained Earnings (Accumulated Deficit)USD | -369,937,000Source | -296,737,000Source | -229,664,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 403,000Source | 65,000Source | 137,000Source |
| Stockholders' Equity Attributable to ParentUSD | 287,610,000Source | -245,360,000Source | -203,105,000Source |
| Liabilities and EquityUSD | 328,743,000Source | 149,645,000Source | 110,040,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 30,924,000Source | 21,148,000Source | 10,605,000Source |
| Operating Lease, Liability, CurrentUSD | 1,938,000Source | 1,529,000Source | 1,224,000Source |
| Accounts Payable, CurrentUSD | 4,998,000Source | 2,852,000Source | 1,166,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,365,000Source | 5,726,000Source | 2,999,000Source |
| Other Liabilities, NoncurrentUSD | 1,547,000Source | — | — |
| Additional Financial Items | |||
| Deferred Revenue, CurrentUSD | 1,557,000Source | 939,000Source | 87,000Source |
| Deferred Revenue, NoncurrentUSD | 3,297,000Source | 1,860,000Source | 255,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source |
| Dividends PayableUSD | — | 0Source | — |
| Short-term InvestmentsUSD | 187,549,000Source | 73,143,000Source | 70,179,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 16,384,000Source | 6,384,000Source | 5,658,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 5,162,000Source | 7,618,000Source | 4,494,000Source |
| Increase (Decrease) in InventoriesUSD | 9,880,000Source | 11,439,000Source | 1,187,000Source |
| Increase (Decrease) in Accounts PayableUSD | 2,098,000Source | 1,515,000Source | 716,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -50,925,000Source | -48,273,000Source | -32,445,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -162,805,000Source | -3,476,000Source | -69,693,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,297,000Source | 3,395,000Source | 402,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 214,874,000Source | 55,615,000Source | 101,029,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,144,000Source | 3,866,000Source | -1,109,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 31,676,000Source | 30,532,000Source | 26,666,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 16,384,000Source | 6,384,000Source | 5,658,000Source |
| DepreciationUSD | 1,573,000Source | 1,151,000Source | 1,226,000Source |
| Dividends PayableUSD | — | 0Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -31,000Source | -23,000Source | -11,000Source |
| General and Administrative ExpenseUSD | 31,025,000Source | 17,869,000Source | 12,225,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Investment Income, InterestUSD | 10,932,000Source | 3,909,000Source | 1,777,000Source |
| Net Income (Loss) Attributable to ParentUSD | -73,200,000Source | -54,756,000Source | -44,099,000Source |
| Nonoperating Income (Expense)USD | -1,519,000Source | -9,505,000Source | -8,249,000Source |
| Operating ExpensesUSD | 127,218,000Source | 81,139,000Source | 42,158,000Source |
| Other Nonoperating Income (Expense)USD | -1,000Source | -2,000Source | -68,000Source |
| Proceeds from Issuance of Common StockUSD | 194,526,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 4,757,000Source | 89,000Source | 10,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 300,000Source | -100,000Source | 100,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 100,251,000Source | 65,124,000Source | 11,995,000Source |
| Cost of RevenueUSD | 44,714,000Source | 29,236,000Source | 5,687,000Source |
| Operating Income (Loss)USD | -71,681,000Source | -45,251,000Source | -35,850,000Source |
| Other Nonoperating Income (Expense)USD | -1,000Source | -2,000Source | -68,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -73,200,000Source | -54,756,000Source | -44,099,000Source |
| Earnings Per Share, BasicUSD per share | -1.81Source | -8.6Source | -8.31Source |
| Earnings Per Share, DilutedUSD per share | -1.81Source | -8.6Source | -8.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 40,529,051Source | 6,365,064Source | 5,303,684Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 40,529,051Source | 6,365,064Source | 5,303,684Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 31,025,000Source | 17,869,000Source | 12,225,000Source |
| Gross ProfitUSD | 55,537,000Source | 35,888,000Source | 6,308,000Source |
| Investment Income, InterestUSD | 10,932,000Source | 3,909,000Source | 1,777,000Source |
| Nonoperating Income (Expense)USD | -1,519,000Source | -9,505,000Source | -8,249,000Source |
| Operating ExpensesUSD | 127,218,000Source | 81,139,000Source | 42,158,000Source |
| Research and Development ExpenseUSD | 34,789,000Source | 26,184,000Source | 17,943,000Source |
| Selling and Marketing ExpenseUSD | 61,404,000Source | 37,086,000Source | 11,990,000Source |
Offerings
Registration 333-284147
- Gross proceeds
- 204000000.0
- Net proceeds
- 189720000.0
- Deal price
- 17.0
- Shares
- 12000000
- Offering price
- $17.00
- Ticker
- BBNX
Filing attachments
d178069dex41.htm · 8-K · 2026-09-17
EX-4.1 3 d178069dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BETA BIONICS, INC. Warrant Shares: Date of Issuance:, 2026 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time …
Read attachment ↗d178069dex991.htm · 8-K · 2026-09-17
EX-99.1 5 d178069dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) - Beta Bionics, Inc. (Nasdaq: BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its common stock. All of the shares are being offered by Beta Bionics. In addition, Beta Bionics intends to gran…
Read attachment ↗d178069dex992.htm · 8-K · 2026-09-17
EX-99.2 6 d178069dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants IRVINE, Calif., Sept. 15, 2026 - Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a …
Read attachment ↗d153052dex991.htm · 8-K · 2026-09-15
EX-99.1 2 d153052dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Beta Bionics Announces FDA Clearance of Mint ™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence ™ as its Next-Generation Insulin Dosing Algorithm Mint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 ───────────────────────────────────────────────────────────────── Manufacturing capacity expected to produce at least 1.5 million disposabl…
Read attachment ↗d153052dex992.htm · 8-K · 2026-09-15
EX-99.2 3 d153052dex992.htm EX-99.2 EX-99.2 Investor Presentation September 2026 Exhibit 99.2 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company,” “we,” “our” or “us…
Read attachment ↗d933339dex991.htm · 8-K · 2025-01-31
EX-99.1 3 d933339dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Irvine, CA., January 31, 2025 - Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the un…
Read attachment ↗